Skip to main content

Aplenzin FDA Approval History

FDA Approved: Yes (First approved April 23, 2008)
Brand name: Aplenzin
Generic name: bupropion hydrobromide
Dosage form: Extended-Release Tablets
Previous Name: BVF-033
Company: Biovail Corporation
Treatment for: Depression

Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Development timeline for Aplenzin

Apr 24, 2008Approval Biovail Receives FDA Approval for Aplenzin (BVF-033)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.